NEUROCRINE BIOSCIENCES INC - NOTE 2.250% 5/1 Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2018 to Q2 2024

Type / Class
Debt / NOTE 2.250% 5/1
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Institutional Holders of NEUROCRINE BIOSCIENCES INC - NOTE 2.250% 5/1 across Reporting Periods

Period Principal Value Change Price (% of par) (Median) Investors
2024 Q2 $0 $0 -$308,037,823 0
2024 Q1 $169,914,000 $308,037,911 +$2,133,529 180.49% 30
2023 Q4 $169,980,000 $294,814,732 -$4,848,036 173.33% 35
2023 Q3 $175,757,000 $262,221,324 +$3,515,689 148.4% 31
2023 Q2 $175,509,000 $224,256,785 +$1,143,164 127.3% 30
2023 Q1 $173,997,600 $234,762,328 -$14,544,253 134.2% 34
2022 Q4 $173,876,600 $275,007,176 +$25,405,051 157.73% 36
2022 Q3 $159,574,000 $223,484,521 -$2,852,351 140.36% 32
2022 Q2 $162,356,000 $215,214,249 -$281,680,883 132.59% 35
2022 Q1 $375,623,000 $494,220,208 -$875,957 131.32% 42
2021 Q4 $376,964,000 $472,462,995 -$26,751,236 125.0% 46
2021 Q3 $394,315,000 $526,509,319 +$32,920,786 133.27% 42
2021 Q2 $370,182,000 $494,304,812 +$22,636,773 133.12% 43
2021 Q1 $353,344,000 $477,872,921 +$37,386,038 135.19% 49
2020 Q4 $327,593,000 $461,538,035 -$216,543,082 138.49% 46
2020 Q3 $498,812,000 $689,306,713 +$15,230,633 137.85% 58
2020 Q2 $472,490,520 $798,559,563 -$32,657,610 166.29% 53
2020 Q1 $505,179,400 $663,088,182 +$3,284,695 128.16% 57
2019 Q4 $500,259,550 $774,162,021 -$20,461,870 153.37% 56
2019 Q3 $519,637,050 $712,746,703 +$4,089,842 137.16% 55
2019 Q2 $518,160,550 $683,227,085 +$54,849,452 131.74% 52
2019 Q1 $477,134,350 $644,162,076 -$35,578,948 135.2% 47
2018 Q4 $507,326,200 $604,492,120 -$14,518,958 119.36% 51
2018 Q3 $485,409,450 $829,851,783 +$27,955,520 170.66% 48
2018 Q2 $472,971,000 $684,711,486 +$680,855,445 144.57% 50
2018 Q1 $2,786,000 $3,660,000 +$3,660,000 131.29% 2